论文部分内容阅读
目的探究血浆置换术联合口服微生态制剂治疗慢加急性肝衰竭(ACLF)的临床疗效。方法 60例ACLF患者,随机分为研究组和对照组,各30例。对照组患者在常规内科治疗基础上行血浆置换术,研究组患者在对照组基础上联合口服微生态制剂治疗,比较两组临床治疗效果。结果研究组患者治疗后血清总胆红素(TBIL)、胆碱酯酶(CHE)、凝血酶原活动度(PTA)、降钙素原(PCT)指标水平改善均优于对照组,差异有统计学意义(P<0.05);研究组治疗有效率(70.0%)高于对照组(56.7%),差异有统计学意义(P<0.05)。结论血浆置换术联合口服微生态制剂治疗ACLF,可进一步改善患者各项生化指标,提高临床疗效,值得推广。
Objective To investigate the clinical efficacy of plasma exchange combined with oral probiotics in the treatment of acute and chronic hepatic failure (ACLF). Methods Sixty patients with ACLF were randomly divided into study group and control group, with 30 cases in each group. The patients in the control group underwent routine plasma therapy based on routine medical treatment. The patients in the study group were treated with oral probiotics on the basis of the control group, and the clinical effects were compared between the two groups. Results After treatment, the levels of total bilirubin (TBIL), cholinesterase (CHE), prothrombin activity (PTA) and procalcitonin (PCT) in the study group were significantly better than those in the control group (P <0.05). The effective rate of study group (70.0%) was higher than that of control group (56.7%), the difference was statistically significant (P <0.05). Conclusion Plasma exchange combined with oral probiotics treatment of ACLF can further improve the biochemical indicators of patients and improve clinical efficacy, it is worth promoting.